This is a repository copy of *The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate.*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/108569/

Version: Supplemental Material

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

Table 1: The assumed annual hospitalisation costs and the assumed hazard rate for mortality conditional on HAQ score

HAQ score	Assumed hospitalisation costs per year	HAQ score at model entry	Hazard ratio for mortality (95% confidence interval) which is applied to age and gender mortality rates.
0.0 – 0.59	£168	0.000	1.00 (referent)
0.60 – 1.09	£103	0.125 – 0.375	1.4 (1.1 to 1.8)
1.10 – 1.59	£365	0.500 – 0.875	1.5 (1.2 to 1.9)
1.60 – 2.09	£524	1.000 – 1.375	1.8 (1.4 to 2.2)
2.10 – 2.59	£1246	1.500 – 1.875	2.7 (2.2 to 3.5)
2.60 – 3.00	£2688	2.000 – 2.375	4.0 (3.1 to 5.2)
		2.500 – 3.000	5.5 (3.9 to 7.7)